Press Releases
ECDGA Applauds FDA Approval of Cobimetinib to Treat Erdheim-Chester Disease
Cobimetinib is an anti-cancer medication that was first approved for the treatment of melanomas.
Een nieuw jaar, een nieuw zorgcentrum voor Erdheim-Chester-patiënten in Nederland
A New Year, a New Care Center for Erdheim-Chester Patients in the Netherlands
Erasmus University Medical Center in Rotterdam joins a network of hospitals skilled in treating Erdheim-Chester ...
NCCN Guidelines for Histiocytosis Clarify Best Practices for Recently-Defined Cancers
New clinical practice guidelines from National Comprehensive Cancer Network focus on workup and management for ...
Rare Disease Care Network Now Serves Michigan Patients
The Erdheim-Chester Disease Global Alliance is proud to announce the first ECD Referral Care Center to be located ...
2021 Erdheim-Chester Disease Virtual Medical Symposium
Tuesday, November 16, 2021: During this conference, medical professionals from around the world gathered to share ...
University of Alabama at Birmingham Joins the ECD Care Center Network
The ECDGA welcomes the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham (UAB) into ...
San Diego Researcher Awarded 2019 ECDGA Research Grant
ECDGA awards a research grant to the University of California-San Diego to improve the understanding of ECD and ...
ECD Caregiver Study Open at Memorial Sloan Kettering
An observational study of informal caregivers (ICs) of patients with Erdheim-Chester Disease (ECD) and other ...
7th Annual International Erdheim-Chester Disease Medical Symposium
The ECD Medical Symposium was hosted by Dr. Lorenzo Dagna at the IRCCS San Raffaele Scientific Institute, ...
2019 Rare Disease Day
Over the last 11 years, Rare Disease Day has become iconic as the global campaign for raising awareness of rare ...
ECDGA Raises Awareness at Endocrinology Conference
Representatives from the ECDGA attended the Endocrinology Society’s annual conference in New Orleans to ...
No results found.